Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

ABSTRACT:

Rationale & objectives

 ± 3,4-Methylenedioxymethamphetamine (MDMA) and psilocybin are currently moving through the US Food and Drug Administration's phased drug development process for psychiatric treatment indications: posttraumatic stress disorder and depression, respectively. The current standard of care for these disorders involves treatment with psychiatric medications (e.g., selective serotonin reuptake inhibitors), so it will be important to understand drug-drug interactions between MDMA or psilocybin and psychiatric medications.

Methods

In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we queried the MEDLINE database via PubMed for publications of human studies in English spanning between the first synthesis of

SUBMITTER: Sarparast A 

PROVIDER: S-EPMC9177763 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature